昂利康：拟向不超过35名特定对象发行不超过约6051.85万股

Group 1 - Company announced the approval of a stock issuance to specific investors, with a maximum of 35 participants, not exceeding 30% of the total share capital prior to the issuance, which amounts to approximately 60.52 million shares [1] - The issuance price will be no less than 80% of the average stock price over the 20 trading days prior to the pricing date [1] - The raised funds, after deducting issuance costs, will be allocated to innovative drug research and industrialization projects, with total investments of approximately 1.196 billion yuan, 677 million yuan, and 518 million yuan for respective projects [1] Group 2 - For the first half of 2025, the company's revenue composition is entirely from the pharmaceutical manufacturing industry, accounting for 100% [2] - The company's market capitalization is currently 8 billion yuan [3]